Sanofi

Alpha Score of 50 reflects moderate overall profile with weak momentum, weak value, strong quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.

Sanofi American Depositary Receipt represents American Depositary Shares (ADS) of Sanofi, a leading French multinational pharmaceutical company. Each ADR corresponds to one-half of an ordinary share listed on Euronext Paris, providing U.S. investors convenient access to the company's equity through a sponsored Level II ADR program managed by J.P. Morgan Chase Bank as depositary, with EQ Shareowner Services as transfer agent. Sanofi focuses on researching, developing, manufacturing, and marketing a broad portfolio of prescription medicines, vaccines, and consumer healthcare products addressing major unmet medical needs in areas such as immunology, neurology, oncology, cardiovascular diseases, and rare diseases. The ADR program ensures holders receive dividends in U.S. dollars, with options for reinvestment, and voting rights at the annual general meeting. Founded in 1973 and headquartered in Paris, France, Sanofi American Depositary Receipt facilitates seamless participation for U.S. shareholders in this global biopharmaceutical leader's ongoing innovations and market presence.